Oxygenta Pharmaceutical's record is one of accumulated distress now laid bare: a going-concern warning in the audit report, negative net worth, and borrowings that nearly doubled in a year. The company changed hands in June 2025, and the new promoter group has already routed transactions worth over twice Oxygenta's own turnover through the company while leaving blank the disclosures that would let an investor assess its financial health.
Key findings
- The auditor flags going concern as net worth turns deeply negative
Critical- For the first time in seven years, the auditor introduced a Key Audit Matter, a risk requiring the most judgement, titled “Material Uncertainty Related to Going Concern,” citing a net loss of ₹17.57 crore, total equity of negative ₹(4,268.68) lakhs, a working capital deficit of ₹(3,181.73) lakhs, and total borrowings of ₹109.57 crore, up 76% from ₹47.33 crore in FY2025. The payroll software lacked an audit trail for the second consecutive year, covering the full twelve months of both FY2025 and FY2026. Prior-year CARO reports show repeated loan defaults in FY2020, FY2022, and FY2023, material deviations of 19-41% in stock statements filed with banks, and serious delays in depositing statutory dues. - Related-party dealings with the new parent exceed twice Oxygenta's own turnover
Major- The company seeks shareholder approval for material related-party transactions with holding company Virupaksha Organics Limited (VOL) of up to ₹250 crore for sales and purchases in FY2027, representing 221% of Oxygenta's annual consolidated turnover of ₹112.98 crore for FY 2025-26. A separate approval covers loans and guarantees of up to ₹200 crore, including ₹100 crore of unsecured inter-corporate borrowings at 9% interest repayable within three years. Actual RPT values with VOL for FY 2025-26 totalled ₹166.60 crore across sales, purchases, borrowings, and interest. The explanatory statement for the loan and guarantee RPT leaves blank the tables for whether VOL's account is classified as NPA, its debt-to-equity ratio, and its debt service coverage ratio. Separately, SEBI observed that a ₹15 crore loan from ARR Capital Investment Private Limited in September 2020 and its subsequent conversion into equity was executed without RPT approval and disclosed only after a two-year delay. - SEBI penalties, a manufacturing licence suspension, and a two-year trading halt form a pattern of regulatory action
Major- BSE suspended trading in Oxygenta's equity shares from 11 October 2019 to 16 July 2021 for non-compliance with SEBI LODR Regulation 31 for two consecutive quarters. SEBI imposed a penalty of ₹5,00,000 on the company on 20 February 2023 for violating the Listing Agreement and LODR Regulations on related-party disclosures, and ₹6,00,000 each on six individuals including the promoters. The Drugs Control Administration suspended Oxygenta's manufacturing licence for seven days during FY2026 for violations of the Drugs and Cosmetics Act. The FY2026 Corporate Governance report lists multiple instances of non-compliance with LODR regulations over the last three years, with fines imposed by BSE. - A complete board and management replacement followed the change in control in June 2025
Major- Virupaksha Organics Limited acquired 55.37% of voting share capital and became the promoter effective 20 June 2025. On the same day, six directors resigned, three independent and three executive, citing the change in management. Six new directors were appointed immediately: two whole-time directors, one non-executive director who is the wife of one whole-time director and sister of the other, and three independent directors. The Managing Director and CFO resigned on 18 August 2025. On 11 December 2025, shareholders approved reclassifying the four outgoing promoter-group individuals, holding 2.55%, to the public category. Post-year-end on 23 May 2026, a new whole-time director and an independent director who also serves on VOL's board were appointed, subject to shareholder approval at the AGM convened on 30 July 2026. - Borrowing limits raised to ₹200 crore while relying on parent support
Major- The board sought and received shareholder approval to raise the borrowing limit under Section 180(1)(c) from ₹50 crore to ₹100 crore in FY2022, and from ₹100 crore to ₹200 crore in FY2025. The company availed ₹46.6 crore of credit from Kotak Mahindra Bank in FY2026 backed by a corporate guarantee from VOL, and an unsecured loan of ₹14.50 crore from VOL on 30 September 2024 at 9% simple interest repayable after three years. Management states the debt-equity ratio of -2.57 times is "not meaningful due to the Company's negative net worth arising from accumulated losses". The company defaulted on term loan repayments to IKF Finance Ltd in FY2023, with amounts paid within 54 days. - The statutory auditor resigned mid-tenure in August 2023; the incoming auditor acknowledged considering the outgoing auditor's concerns
Major- Gowri Shankar & Associates resigned effective 12 August 2023, during a second five-year term approved by shareholders in September 2022, stating "no material reason other than those provided". A.M. Reddy & D.R. Reddy was appointed on 4 September 2023 and re-appointed for five years until the 35th AGM in 2027-28. The incoming auditor's CARO report for FY2024 states it "has taken into consideration the issues, objections or concerns raised by the outgoing auditors". Total statutory audit fees remained at ₹5-6 lakh per annum across the three years from FY2024 through FY2026.
What to watch
- Going-concern resolution and audit trail. The FY2027 audit report will show whether the going-concern Key Audit Matter is resolved and whether the payroll audit trail deficiency is remedied, following the FY2026 annual report dated 31 March 2026.
- Auditor term completion. A.M. Reddy & D.R. Reddy's five-year term runs until the 35th AGM in 2027-28, as stated in the FY2026 Annual Report.
- Director appointments at the 33rd AGM. The appointments of Mr. Amireddy Venkatesu Reddy as Whole-Time Director and Mr. Janardhana Reddy Yeddula as Independent Director are subject to shareholder approval at the AGM convened on 30 July 2026.
- Parent loan maturity. The unsecured ₹14.50 crore loan from Virupaksha Organics Limited matures three years from 30 September 2024, with full principal and accrued interest repayable at that date.
- Deferred tax asset recovery. The ₹17.41 crore net deferred tax asset recognised as at 31 March 2026 is contingent on the company generating sufficient future taxable profits against unabsorbed depreciation and carried-forward losses of ₹76.1 crore.
Bottom line: This is a record of a company that exhausted its standalone viability and was acquired by a related entity that now dominates its commercial and financial life. The going-concern warning, the blank related-party disclosures, and the six-year run of operating losses sit alongside a deferred tax asset that assumes a profitability the company has not demonstrated. The new board and the scale of parent-company dealing mean the story from here is written inside Virupaksha Organics Limited, and the disclosures that matter most are the ones left blank. Watch the FY2027 audit report and the maturity of the unsecured parent loan.